Total Valuation
Beximco Pharmaceuticals Limited Sponsored GDR RegS has a market cap or net worth of 65.67B. The enterprise value is 201.79M .
Market Cap65.67B
Enterprise Value201.79M
Share Statistics
Beximco Pharmaceuticals Limited Sponsored GDR RegS has 446,112,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding446,112,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Beximco Pharmaceuticals Limited Sponsored GDR RegS’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count6,000
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Beximco Pharmaceuticals Limited Sponsored GDR RegS is 4.6. Beximco Pharmaceuticals Limited Sponsored GDR RegS’s PEG ratio is ―.
PE Ratio4.6
PS Ratio0.00
PB Ratio0.00
Price to Fair Value―
Price to FCF0.00
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Beximco Pharmaceuticals Limited Sponsored GDR RegS had revenue of ― and earned 4.61B in profits. Earnings per share was ―.
Revenue―
Gross Profit17.31B
Operating Income7.17B
Pretax Income―
Net Income4.61B
EBITDA9.37B
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Beximco Pharmaceuticals Limited Sponsored GDR RegS pays an annual dividend of 2.32 p, resulting in a dividend yield of 4.3%
Dividend Per Share2.32 p
Dividend Yield4.3%
Payout Ratio19.59%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.10
52-Week Price Change28.45%
50-Day Moving Average56.41
200-Day Moving Average45.32
Relative Strength Index (RSI)36.49
Average Volume (3m)24.52K
Important Dates
Beximco Pharmaceuticals Limited Sponsored GDR RegS upcoming earnings date is Feb 2, 2027, TBA (Confirmed).
Last Earnings DateJun 24, 2026
Next Earnings DateFeb 2, 2027
Ex-Dividend Date―
Financial Position
Beximco Pharmaceuticals Limited Sponsored GDR RegS as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Beximco Pharmaceuticals Limited Sponsored GDR RegS has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Beximco Pharmaceuticals Limited Sponsored GDR RegS EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Beximco Pharmaceuticals Limited Sponsored GDR RegS has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt―
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Beximco Pharmaceuticals Limited Sponsored GDR RegS is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast3.86%
EPS Growth Forecast19.11%